✦HEALTH · 30% off Purgo Labs✦
Compound Family Guide

GHRH Analogues

The complete reference for growth hormone-releasing hormone analogues — sermorelin, CJC-1295, and tesamorelin. Mechanism, half-life comparison, FDA status and the human evidence. Research use only; we do not publish dosing.

3 GHRH analogues covered
FDA approval status
Head-to-head comparisons
Human evidence
Background

What Is GHRH?

Growth hormone-releasing hormone (GHRH) is a 44-amino acid peptide produced by the hypothalamus that stimulates the anterior pituitary to synthesize and secrete growth hormone (GH). It is the primary upstream regulator of the GH/IGF-1 axis, acting in concert with somatostatin (which inhibits GH release) to produce the characteristic pulsatile GH secretion pattern observed in healthy individuals.

GHRH analogues are synthetic peptides designed to mimic or improve upon endogenous GHRH. The key engineering challenge is extending the extremely short half-life of native GHRH (~7 minutes in plasma) while preserving receptor selectivity. Each approved or investigational analogue takes a different structural approach to this problem, resulting in meaningfully different pharmacokinetic profiles and clinical applications.

Mechanism

Shared Mechanism of Action

GHRH Receptor Binding

All GHRH analogues bind the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary. This G-protein coupled receptor activates adenylyl cyclase, increasing intracellular cAMP.

GH Synthesis & Release

Elevated cAMP activates protein kinase A (PKA), which phosphorylates transcription factors including Pit-1, stimulating GH gene transcription and triggering exocytosis of stored GH granules.

IGF-1 Upregulation

Released GH travels to the liver and peripheral tissues, stimulating IGF-1 production. IGF-1 mediates most of GH's anabolic effects — muscle protein synthesis, lipolysis, and bone mineralization.

Negative Feedback Preservation

Unlike exogenous HGH, GHRH analogues preserve the somatostatin-mediated negative feedback loop. This prevents supraphysiological GH levels and maintains pituitary sensitivity over time.

The Compounds

GHRH Analogue Profiles

Most Studied

Sermorelin

~11 min
FDA StatusWithdrawn (Geref, 2008)
Primary UseGH deficiency, anti-aging, sleep quality
PotencyModerate
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂
Longest Half-Life

CJC-1295

~8 days (with DAC) / ~30 min (without DAC)
FDA StatusNot approved
Primary UseSustained GH elevation, muscle growth, fat loss
PotencyHigh (DAC extends half-life dramatically)
Modified GHRH(1-29) with DAC (Drug Affinity Complex) at Lys₁₇
FDA-Approved

Tesamorelin

~26 min
FDA StatusFDA-approved (Egrifta, 2010) — HIV lipodystrophy
Primary UseVisceral fat reduction, body composition
PotencyHigh (N-terminal modification increases stability)
trans-3-hexenoic acid-GHRH(1-44)-NH₂
GHRP (different receptor)

Ipamorelin

~2 hours
FDA StatusNot approved
Primary UseGH pulse amplification, lean mass, sleep
PotencySelective GHRP — complements GHRH analogues
Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (GHRP, not GHRH — often discussed alongside)
Comparison

GHRH Analogue Comparison Table

ParameterSermorelinCJC-1295Tesamorelin
StructureGHRH(1-29)GHRH(1-29) + DAC modificationGHRH(1-44) + N-terminal hexenoic acid
Half-life~11 minutes~8 days (with DAC)~26 minutes
GH release patternPulsatile (physiological)Sustained blunted pulsePulsatile (stronger than sermorelin)
FDA approvalWithdrawn 2008 (was approved for children)NoneYes (2010, HIV-associated abdominal fat)
Human evidencePaediatric GH deficiency (historic)Early PK studies; development stoppedPhase 3 trials in HIV lipodystrophy
Established doseOnly on the withdrawn labelNoneSet by the Egrifta label, for its approved use
Combinations

GHRH analogues with GHRPs: what the evidence covers

Two GHRH analogues act on the same receptor, so pairing them adds nothing in principle. Pairing a GHRH analogue with a growth hormone-releasing peptide (GHRP) such as ipamorelin is different: the GHRP acts on the ghrelin receptor (GHS-R1a), and in studies of GHRH and GHRP given together the GH response was larger than with either alone.

That is the whole evidence base for the "stacks" sold online. No trial has tested sermorelin, CJC-1295 or tesamorelin combined with ipamorelin for fat loss, muscle, sleep or ageing, and no dose or schedule for any combination has been established. Compound Review does not publish dosing or stack protocols. Outside tesamorelin's approved use, these compounds are sold for laboratory research only and are not for human or animal consumption.

FAQ

Frequently Asked Questions

What is a GHRH analogue?

A GHRH analogue is a synthetic peptide that mimics growth hormone-releasing hormone (GHRH), the hypothalamic peptide that stimulates the pituitary to produce and release growth hormone. Unlike exogenous HGH, GHRH analogues work upstream — they stimulate the body's own GH production rather than replacing it.

What is the difference between GHRH analogues and GHRPs?

GHRH analogues (sermorelin, CJC-1295, tesamorelin) bind the GHRH receptor and stimulate GH synthesis and release via the cAMP pathway. GHRPs (growth hormone-releasing peptides) such as ipamorelin and GHRP-6 bind the ghrelin receptor (GHS-R1a) and amplify GH release via a different pathway. In studies, giving one of each produced larger GH responses than either alone; no combination has been trialled for a health outcome.

Which GHRH analogue is best for fat loss?

Tesamorelin is the only one with trial evidence: in Phase 3 trials in people with HIV-associated abdominal fat, visceral fat fell by roughly 15% over 26 weeks versus placebo, which led to its FDA approval for that use alone. CJC-1295 and sermorelin have no fat-loss trials, and none of these has been shown to reduce fat in people without HIV lipodystrophy.

Is any GHRH analogue proven for anti-aging or sleep?

None has evidence for either. Sermorelin is often marketed for ageing and sleep because it produces pulsatile GH release, but no controlled trial has shown an anti-ageing or sleep benefit in healthy adults, and its US approval (for children with GH deficiency) was withdrawn in 2008.

Is there evidence for combining GHRH analogues?

Two GHRH analogues share a receptor, so combining them adds nothing in principle. GHRH plus GHRP pairs gave larger GH responses in studies, but no combination has been trialled for any outcome, and we do not publish stack or dosing protocols.

Research-Grade Supply

Source GHRH Analogues for Research

Purgo Labs provides pharmaceutical-grade GHRH analogue peptides with third-party COA verification, ≥99% purity, and cGMP manufacturing standards. Use code HEALTH for 20% off.

Shop Purgo Labs

Related Guides